Umberto Malapelle 1 , Marcello Tiseo 2 , Ana Vivancos 3, Joshua Kapp 4, M. Josè Serrano 5,6,7, and Markus Tiemann 8,*. Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European Perspective. Molecular Pathology in Solid Tumors. 2021

Dmitri Atiakshin  1   2 , Igor Buchwalow  3 , Peter Horny  4 , Markus Tiemann  5. Protease profile of normal and neoplastic mast cells in the human bone marrow with special emphasis on systemic mastocytosis. Histochem Cell Biol. 2021 May;155(5):561-580. doi: 10.1007/s00418-021-01964-3. Epub 2021 Jan 25. PMID: 33492488

C. Hoffmann, J.Tepel, M. Tiemann. Morbus Castleman – ein seltenes, heterogenes Krankheitsbild. Best Practice Onkologie 2021

Fehr A. et al. Mucoepidermoid carcinoma of the salivary glands revisited with special reference to histologic grading and CRTC1/3-MAML2 genotyping. Virchows Arch. 2021 Nov;479(5):975-985. doi: 10.1007/s00428-021-03146-x. Epub 2021 Jul 7. PMID: 34231055

Jóri, B.; Schatz, S.; Kaller, L.; Kah, B.; Roeper, J.; Ramdani, H.O.; Diehl, L.; Hoffknecht, P.; Grohé, C.; Griesinger, F.; Tiemann, M.; Heukamp, L.C.; Falk, M. Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy. Cancers 2021, 13(12), 2861

BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy. European Journal of Cancer 2021; DOI: 10.1016/j.ejca.2021.02.036

Reinartz G et al. Renaissance of Radiotherapy in Intestinal Lymphoma? 10-Year Efficacy and Tolerance in Multimodal Treatment of 134 Patients: Follow-up of Two German Multicenter Consecutive Prospective Phase II Trials. Oncologist 2020; May;25(5):e816-e832. doi: 10.1634/theoncologist.2019-0783

Haentschel M et al. Influence of Biopsy Technique on Molecular Genetic Tumor Characterization in Non-Small Cell Lung Cancer-The Prospective, Randomized, Single-Blinded, Multicenter PROFILER Study Protocol. Diagnostics (Basel) 2020; Jul 6;10(7):459. doi: 10.3390/diagnostics10070459

Boecker W et al. Twenty-Eight Cases of Extraocular Sebaceous Carcinoma: A Correlative Clinicopathological and Immunohistochemical Analysis of Extraocular Sebaceous Carcinomas and Benign Sebaceous Gland Tumors. Am J Dermatopathol 2020; Jun 15. DOI: 10.1097/DAD.0000000000001667

Bermudez M et al. Biological Characterization, Mechanistic Investigation and Structure-Activity Relationships of Chemically Stable TLR2 Antagonists. ChemMedChem 2020; Jul 20;15(14):1364-1371. doi: 10.1002/cmdc.202000060

Buchwalow I et al. Signal amplification in immunohistochemistry: loose-jointed deformable heteropolymeric HRP conjugates vs. linear polymer backbone HRP conjugates. Acta Histochem 2013; Jul;115(6):587-94. doi: 10.1016/j.acthis.2012.12.008

Petersen I et al. EGFR immunohistochemistry as biomarker for antibody-based therapy of squamous NSCLC – Experience from the first ring trial of the German Quality Assurance Initiative for Pathology (QuIP ®). Pathol Res Pract 2017; Sept 213(12). doi: 10.1016/j.prp.2017.09.021

Atiakshin D et al. Mast cells and collagen fibrillogenesis. Histochem Cell Biol 2020; Jul;154(1):21-40. DOI: 10.1007/s00418-020-01875-9

Boecker W et al. Multicolor immunofluorescence reveals that p63- and/or K5-positive progenitor cells contribute to normal breast epithelium and usual ductal hyperplasia but not to low-grade intraepithelial neoplasia of the breast. Virchows Arch 2017; May;470(5):493-504. doi: 10.1007/s00428-017-2073-7

Reck M et al. Therapiestandards und Perspektiven beim nichtkleinzelligen Lungenkarzinom im Stadium IV. Onkologie 2012; 35(Suppl 3):10–13. DOI: 10.1159/000338986

Tiemann M et al. Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease. BMC Res Notes 2020; Mar 7;13(1):139. DOI: 10.1186/s13104-020-04975-w

Atiakshin D et al. Characterization of mast cell populations using different methods for their identification. Histochem Cell Biol 2017; Jun;147(6):683-694. doi: 10.1007/s00418-017-1547-7

Buchwalow I et al. Identification of autofluorescent cells in human angioimmunoblastic T-cell lymphoma. Histochem Cell Biol 2017; Jun;147(6):683-694. DOI: 10.1007/s00418-017-1547-7

Buchwalow I et al. The contribution of Paul Ehrlich to histochemistry: a tribute on the occasion of the centenary of his death. Virchows Arch 2015; Jan;466(1):111-6. doi: 10.1007/s00428-014-1677-4

Berger LA et al. Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib. J Thorac Oncol 2018; Dec;13(12):e243-e246. DOI: 10.1016/j.jtho.2018.08.2025 I2

Keppens C et al. Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe. J Mol Diagn 2018; Jul;20(4):483-494. DOI: 10.1016/j.jmoldx.2018.03.006

Hallas C et al. Immunohistochemical distinction of ABC and GCB in extranodal DLBCL is not reflected in mutation patterns. Leuk Res 2019; Jan;76:107-111. DOI: 10.1016/j.leukres.2018.10.003

. Multiple immunolabeling with antibodies from the same host species in combination with tyramide signal amplification. Acta Histochem 2018; Jul;120(5):405-411. DOI: 10.1016/j.acthis.2018.05.002

Boecker W et al. Spatial analysis of p63, K5 and K7 defines two groups of progenitor cells that differentially contribute to the maintenance of normal sebaceous glands, extraocular sebaceous carcinoma and benign sebaceous tumors. J Dermatol 2019; Mar;46(3):249-258. DOI: 10.1111/1346-8138.14765

Reinartz G et al. Favorable radiation field decrease in gastric marginal zone lymphoma : Experience of the German Study Group on Gastrointestinal Lymphoma (DSGL). Strahlenther Onkol 2019; DOI: 10.1007/s00066-019-01446-5 Jun;195(6):544-557.

Stenzinger A et al. Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study. J Thorac Oncol 2020; Jul;15(7):1177-1189. DOI: 10.1016/j.jtho.2020.01.023

Scheel AH et al. Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer. Histopathology 2018; Feb;72(3):449-459. doi: 10.1111/his.13375

Atiakshin D et al. Tryptase as a polyfunctional component of mast cells. Histochem Cell Biol 2018; May;149(5):461-477. DOI: 10.1007/s00418-018-1659-8

Atiakshin D et al. Mast cell chymase: morphofunctional characteristics. Histochem Cell Biol 2019; Oct;152(4):253-269. DOI: 10.1007/s00418-019-01803-6

Boecker W et al. Adenosquamous Carcinoma of the Pancreas Comprise a Heterogeneous Group of Tumors With the Worst Outcome: A Clinicopathological Analysis of 25 Cases Identified in 562 Pancreatic Carcinomas Resected With Curative Intent. Pancreas 2020; May/Jun 2020;49(5):683-691. doi: 10.1097/MPA.0000000000001548

Schem C et al. One-step nucleic acid amplification-a molecular method for the detection of lymph node metastases in breast cancer patients; results of the German study group. Virchows Arch 2009; Feb;454(2):203-10. doi: 10.1007/s00428-008-0703-9

Tiemann K et al. Solid pseudopapillary neoplasms of the pancreas show an interruption of the Wnt-signaling pathway and express gene products of 11q. Mod Pathol 2007; Sep;20(9):955-60. doi: 10.1038/modpathol.3800902

Minckwitz G et al. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer–results from the GeparQuattro study (GBG 40). Breast Cancer Res Treat 2011; Apr;132(3):863-70. doi: 10.1007/s10549-011-1621-0

Tiemann K et al . Solid pseudopapillary neoplasms of the pancreas are associated with FLI-1 expression, but not with EWS/FLI-1 translocation. Mod Pathol 2006; Nov;19(11):1409-13. doi: 10.1038/modpathol.3800664

Sipos B et al. Lymphatic spread of ductal pancreatic adenocarcinoma is independent of lymphangiogenesis. J Pathol 2005; Nov;207(3):301-12. doi: 10.1002/path.1840

Maass N et al. Final safety and efficacy analysis of a phase I/II trial with imatinib and vinorelbine for patients with metastatic breast cancer. Clinical Trial 2014; 87(5):300-10. doi: 10.1159/000365553. Epub 2014 Aug 26

Boecker W et al. Squamous/epidermoid differentiation in normal breast and salivary gland tissues and their corresponding tumors originate from p63/K5/14-positive progenitor cells. Virchows Arch 2015; Jan;466(1):21-36. doi: 10.1007/s00428-014-1671-x. Epub 2014 Oct 26

Boecker W et al. K5/K14-positive cells contribute to salivary gland-like breast tumors with myoepithelial differentiation. Mod Pathol 2013; Aug;26(8):1086-100. doi: 10.1038/modpathol.2013.45

Hallas C et al. BCL9L expression in pancreatic neoplasia with a focus on SPN: a possible explanation for the enigma of the benign neoplasia. BMC Cancer 2016; Aug 18;16:648. DOI: 10.1186/s12885-016-2707-1

Loibl S et al. Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. Clin Cancer Res 2016; Jun 1;22(11):2675-83. DOI: 10.1158/1078-0432.CCR-15-0965

Buchwalow I et al. Oxidative stress and NO generation in the rat pancreatitis induced by pancreatic duct ligation. Acta Histochem 2017; Apr;119(3):252-256. DOI: 10.1016/j.acthis.2017.01.010

Buchwalow I et al. L-arginine-NO-cGMP signalling pathway in pancreatitis. Sci Rep 2013; 2013;3:1899. DOI: 10.1038/srep01899

Boecker W et al. Cellular organization and histogenesis of adenosquamous carcinoma of the pancreas: evidence supporting the squamous metaplasia concept. Histochem Cell Biol 2020; Jul;154(1):97-105. doi: 10.1007/s00418-020-01864-y

Locati LD et al. Immunohistochemical and molecular profile of salivary gland cancer in children. Pediatr Blood Cancer 2017; Sep;64(9). doi: 10.1002/pbc.26468

Boecker W et al. Spatially correlated phenotyping reveals K5-positive luminal progenitor cells and p63-K5/14-positive stem cell-like cells in human breast epithelium. Lab Invest 2018; Aug;98(8):1065-1075. doi: 10.1038/s41374-018-0054-3

Buchwalow I et al. New Insight into the Role of Nitric Oxide Pathways in Pancreas. Acta Histochem Cytochem 2018; Dec 20;51(6):167-172. doi: 10.1267/ahc.1802

Michels S et al. Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients. J Thorac Oncol 2016; Jan;11(1):122-7. doi: 10.1016/j.jtho.2015.09.016

Menon R et al. A Novel EGFR(C797) Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture-Based Next-Generation Sequencing Assay. J Thorac Oncol 2016; Sep;11(9):e105-7. doi: 10.1016/j.jtho.2016.04.005

Ortiz-Cuaran S et al. Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. Clin Canc Res 2016; Oct 1;22(19):4837-4847. doi: 10.1158/1078-0432.CCR-15-1915

Scheel AH et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol 2016; Oct;29(10):1165-72. doi: 10.1038/modpathol.2016.117

Latteyer S et al. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer. Endocrine 2016; Dec;54(3):733-741. doi: 10.1007/s12020-016-1080-9

Pajtler KW et al. The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models. Oncotarget 2017; Jan 24;8(4):6730-6741. doi: 10.18632/oncotarget.14268

Michels S et al. ALKG1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor. NPJ Precis Oncol 2017; Mar 20;1(1):4. doi: 10.1038/s41698-017-0004-3

Gottlieb A et al. RITA displays anti-tumor activity in medulloblastomas independent of TP53 status. Oncotarget 2017; Apr 25;8(17):27882-27891. doi: 10.18632/oncotarget.15840

Müller J et al. Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens. J Thorac Oncol 2017; Oct;12(10):1503-1511. doi: 10.1016/j.jtho.2017.07.014

Brägelmann J et al. Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma. Cell Rep 2017; Sep 19;20(12):2833-2845. doi: 10.1016/j.celrep.2017.08.082

Christopoulos P et al. Risk stratification of EGFR + lung cancer diagnosed with panel-based next-generation sequencing. Lung Cancer 2020; Oct;148:105-112. doi: 10.1016/j.lungcan.2020.08.007

Schatz S et al. Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer. Cancers 2020; Jun 24;12(6):1685. doi: 10.3390/cancers12061685

Bochtler et al. Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.  Int J Cancer 2020; Jun 1;146(11):3053-3064. doi: 10.1002/ijc.32882. Epub 2020 Mar 11

Wagener-Ryczek S et al. Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors. BMC Cancer 2020; May 12;20(1):408. doi: 10.1186/s12885-020-06920-3

Volz C et al. Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC. Cell Rep 2020; Apr 28;31(4):107568. doi: 10.1016/j.celrep.2020.107568

Roeper J et al. TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC.  Oncotarget 2020; Jan 21;11(3):250-264. doi: 10.18632/oncotarget.27430

Thunnissen E et al. ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib. Lung Cancer 2019; Dec;138:13-18. doi: 10.1016/j.lungcan.2019.09.023

Michels S et al. Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. JCO Precis Oncol 2019; Mar 27;3. doi: 10.1200/PO.18.00210

Michels S et al. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. J Thorac Oncol 2019; Jul;14(7):1266-1276. doi: 10.1016/j.jtho.2019.03.020.

Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica. Tumori 2018 Dec;104(6):NP38-NP41. doi: 10.1177/0300891618763215

Frank R et al. Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC). Clin Canc Res 2018; Jul 1;24(13):3087-3096. doi: 10.1158/1078-0432.CCR-17-3416

Plenker D et al. Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients. Clin Canc Res 2018; Mar 15;24(6):1337-1343. doi: 10.1158/1078-0432.CCR-17-3001

Scheel AH et al. Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer. Histopathology 2018; Feb;72(3):449-459. doi: 10.1111/his.13375

Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non-Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy. J Thorac Oncol 2017; Nov;12(11):e186-e188. doi: 10.1016/j.jtho.2017.07.018